Zacks Investment Research downgraded shares of SEATTLE GENETIC (SGEN) from OUTPERFORM to NEUTRAL on June 10, 2013, with a target price of $41.20.
Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SEATTLE GENETIC (SGEN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment